Millions of heart failure patients are without a viable treatment
Severe functional mitral regurgitation (FMR) affects millions of patients. Due to high surgical risks, only a small percentage of patients undergo open-heart valve surgery. Nearly half of the remaining patients, who are treated with medication only, will die within two years.
Converting open-heart valve surgery to a transcatheter procedure
VALFIX system offers a solution to the millions of patients currently without viable treatment.
VALFIX’s innovative and game-changing system allows cardiologists to perform transcatheter mitral valve repair procedures to alleviate heart failure symptoms, improve quality of life, and save lives.
Minimally Invasive Procedure
Backed By Leading
Surgeons & Cardiologists
“What I like about the VALFIX device is that it serves as a standalone annuloplasty device, but it can serve also as a platform… it just provides a lot of flexibility of what the future may bring“
“The annuloplasty option is very, very important to achieve immediate and long-term outcomes which are sustainable over time. It is exactly what we need today to achieve and have on the shelf to offer to our patients.”
VALFIX was founded with a mission to heal hearts and save lives by experienced medical device entrepreneurs and a leading interventional cardiologist
VALFIX’s technology responds to the current large and clinically significant unmet need.
VALFIX’s proprietary technology has passed proof of concept and is moving forward to clinical trials.